profit from every $100 of sales.
$0$100
BioHarvest Sciences
$1.51-7.67% today
-79.4% in 1 year
1-year low $1.451-year high $7.30
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What BioHarvest Sciences sold, what it kept, and what it did with the cash.
Sales went from $5.50 million in 2022 to $34.5 million in 2025, with -$11.1 million of profit last year.
SalesProfit
BioHarvest Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BioHarvest Sciences | No profit yet | ||
 Nutrien | 14.9× · Cheap | ||
 CF Industries Holdings | 12.6× · Cheap | ||
 Industries Qatar Q.P.S.C. | 14.8× · Cheap | ||
 Qinghai Salt Lake Industry Co.,Ltd | 13.6× · Cheap |
AI analysis
An AI analyst reads BioHarvest Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 5 | 13 | 25 | 35 | |
| 1 | 6 | 14 | 20 | |
| -11 | -10 | -7 | -6 | |
| -9 | -10 | -7 | -7 | |
| -11 | -13 | -13 | -11 | |
| -0.70 | -0.93 | -0.80 | -0.60 | |
| 22.2% | 44.5% | 55.4% | 59.3% | |
| -193.0% | -78.6% | -27.7% | -16.2% | |
| -204.4% | -99.1% | -51.3% | -32.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 9 | 15 | 25 | 48 |
| Cash | 2 | 5 | 2 | 23 |
| Total debt | 11 | 22 | 14 | 14 |
| Total liabilities | 15 | 30 | 24 | 22 |
| -6 | -15 | 1 | 25 | |
| 13 | 14 | 16 | 18 | |
| -167.9% | -111.9% | -42.6% | -16.7% | |
| 189.5% | 84.6% | -970.9% | -43.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -9 | -9 | -7 | -7 | |
| 1 | 1 | 3 | 2 | |
| -10 | -10 | -10 | -10 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 2.9×
- 1.0×
- –
- –
- -28.1%
- -32.6%
- 0.0%
Profitability
- 59.3%
- -16.2%
- -32.3%
- -19.5%
- -13.4%
- -140.4%
- -158.6%
- -23.4%
- -13.9%
- 15.4%
Growth
- +84.5%
- –
- −0.7%
- –
- +10.3%
Financial health
- -1.3×
- 0.55
- 29.6%
- -0.9×
- 3.97
- 3.38
- 0.72
How it ranks in Materials
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 989
Bottom 2%of 954
Top 1%of 940
Bottom 2%of 990
What analysts expect
- Average price target
- $10.00
- Range
- $10.00 – $10.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.11 | -0.13 | +15.4% |
| Mar 31, 2026 | -0.10 | -0.11 | +4.8% |
| Nov 13, 2025 | -0.14 | -0.14 | +0.0% |
| Aug 11, 2025 | -0.15 | -0.11 | −36.4% |
| May 15, 2025 | -0.13 | -0.15 | +13.3% |
| Mar 31, 2025 | -0.17 | -0.12 | −41.7% |
| Nov 25, 2024 | -0.16 | -0.05 | −220.0% |
| Oct 23, 2024 | -0.04 | -0.10 | +58.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
40No pass
Philip Fisher
50No pass
Peter Lynch
68Pass
Joel Greenblatt
2No pass
Charlie Munger
36No pass
Terry Smith
42No pass
Questions about BioHarvest Sciences
Is BioHarvest Sciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BioHarvest Sciences AI analysis
What does BioHarvest Sciences do?
BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. It is in Agricultural Inputs.
Does BioHarvest Sciences pay a dividend?
No. BioHarvest Sciences does not pay a dividend at the moment.
Is BioHarvest Sciences stock halal?
No. BioHarvest Sciences does not pass our halal screen: its debt is 41% of its market value, at or above the 33% limit. How we check
How has BioHarvest Sciences stock done over the past year?
Down 79.4% over the past twelve months, to $1.51. It traded between $1.45 and $7.30 and is 79.4% below its high.
Who are BioHarvest Sciences's competitors?
The largest listed companies in the same industry are Nutrien, CF Industries Holdings, Industries Qatar Q.P.S.C. and Qinghai Salt Lake Industry Co.,Ltd. The peers table on this page compares their profit, growth and price with BioHarvest Sciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.